Saving Lives, Buying Time: Economics of Malaria Drugs in an Age ofResistance examines the history of malaria treatments, provides an overviewof the current drug crisis, and offers recommendations on maximizingaccess to and effectiveness of antimalarial drugs. The book finds that most peoplein endemic countries will not have access to currently effective combinationtreatments, which should include an artemisinin, without financing from the global community. Without funding for effective treatment, malaria mortality could double over the next 10 to 20 years and transmission will intensify.

Saving Lives, Buying Time: Economics of Malaria Drugs in an Age ofResistance examines the history of malaria treatments, provides an overviewof the current drug crisis, and offers recommendations on maximizingaccess to and effectiveness of antimalarial drugs. The book finds that most peoplein endemic countries will not have access to currently effective combinationtreatments, which should include an artemisinin, without financing from the global community. Without funding for effective treatment, malaria mortality could double over the next 10 to 20 years and transmission will intensify.

Saving Lives, Buying Time: Economics of Malaria Drugs in an Age ofResistance examines the history of malaria treatments, provides an overviewof the current drug crisis, and offers recommendations on maximizingaccess to and effectiveness of antimalarial drugs. The book finds that most peoplein endemic countries will not have access to currently effective combinationtreatments, which should include an artemisinin, without financing from the global community. Without funding for effective treatment, malaria mortality could double over the next 10 to 20 years and transmission will intensify.

Saving Lives, Buying Time: Economics of Malaria Drugs in an Age ofResistance examines the history of malaria treatments, provides an overviewof the current drug crisis, and offers recommendations on maximizingaccess to and effectiveness of antimalarial drugs. The book finds that most peoplein endemic countries will not have access to currently effective combinationtreatments, which should include an artemisinin, without financing from the global community. Without funding for effective treatment, malaria mortality could double over the next 10 to 20 years and transmission will intensify.